8-K: Silexion Reports Deepening Losses, Going Concern Warning

Silexion Therapeutics Corp. disclosed significantly increased net losses and cash burn for 2024, alongside recent capital raises and a going concern warning, following multiple reverse share splits.

Summary

• Silexion Therapeutics Corp. reported a net loss of $16,519 thousand for the year ended December 31, 2024, a substantial increase from $5,108 thousand in 2023.
• Operating expenses surged to $12,571 thousand in 2024 from $4,681 thousand in 2023, driven by increased research and development and general and administrative costs.
• Cash and cash equivalents decreased significantly to $1,187 thousand as of December 31, 2024, from $4,595 thousand at the end of 2023.
• The company completed a 1-for-15 reverse share split on July 28, 2025, and a prior 1-for-9 reverse share split on November 27, 2024, retroactively adjusting all share and per-share amounts.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows.
• Subsequent to year-end, the company raised approximately $5,000 thousand in gross proceeds from a public offering on January 15, 2025, and an additional $3,276 thousand from an induced warrant exercise transaction on January 29, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, evidenced by significantly increased losses, high cash burn, and an explicit going concern warning. While recent capital raises provide temporary liquidity, they do not address the fundamental lack of revenue and high operational costs inherent in its development stage. The multiple reverse stock splits indicate significant share price depreciation and potential investor concern.

Positives

• Successfully completed a SPAC merger on August 15, 2024, becoming a Nasdaq-listed entity (SLXN, SLXNW).
• Raised significant capital totaling approximately $8,276 thousand in gross proceeds through a public offering and induced warrant exercise in January 2025, improving short-term liquidity.
• Secured an Equity Line of Credit (ELOC) for up to $15,000 thousand until December 31, 2025, providing a potential source of future funding.
• The capital deficiency improved from $(15,476) thousand in 2023 to $(3,989) thousand in 2024, likely due to the SPAC merger.

Negatives

• Net loss for the year ended December 31, 2024, significantly increased to $16,519 thousand from $5,108 thousand in 2023.
• Operating expenses more than doubled, rising to $12,571 thousand in 2024 from $4,681 thousand in 2023.
• General and administrative expenses saw a massive increase to $6,756 thousand in 2024 from $973 thousand in 2023.
• Cash and cash equivalents declined sharply to $1,187 thousand at year-end 2024 from $4,595 thousand at year-end 2023.
• Negative operating cash flows increased to $(8,396) thousand in 2024 from $(4,529) thousand in 2023, indicating a higher cash burn rate.
• Total liabilities significantly increased to $6,852 thousand in 2024 from $2,255 thousand in 2023.
• The company has not yet generated revenues and is still in its development and clinical stage.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses from operations and negative cash flows.
• Uncertainty in obtaining future funding to finance research and development activities, general and administrative expenses, and working capital.
• Geopolitical risks from ongoing hostilities in Israel, which could adversely affect operations and ability to raise capital, despite current assessment of no material impact.
• Reliance on future sales of products to generate royalties payable to the Israeli Innovation Authority (IIA), with an outstanding potential obligation of approximately $6.5 million including interest as of December 31, 2024.
• Potential for significant dilution from future equity financings, including the ELOC agreement and conversion of promissory notes and warrants.

Future Outlook

Management expects to continue incurring losses and negative cash flows from operations. The company will need to finance future research and development activities, general and administrative expenses, and working capital through further fundraising. There is no assurance that such funding will be successfully obtained.

Management Comments

• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the date these financial statements are issued.
• The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees.
• The Company does not believe that the war [in Israel] will have any material impact on its ongoing operations as most trials are not executed in Israel.

Industry Context

Silexion Therapeutics operates in the highly capital-intensive and high-risk biotechnology sector, specifically focusing on innovative treatments for pancreatic cancer using siRNAs. Companies in this stage typically incur significant research and development expenses and operate at a loss for extended periods, relying heavily on external financing to fund clinical trials and operational costs. The substantial increase in R&D and G&A expenses, coupled with a significant cash burn, is characteristic of a development-stage biotech firm advancing its pipeline. The reliance on reverse stock splits and multiple capital raises, including an equity line of credit, reflects the common challenge of maintaining Nasdaq listing requirements and securing sufficient liquidity in this industry.

Comparison to Industry Standards

• Cash Burn: Silexion's net cash used in operating activities increased from $4,529 thousand in 2023 to $8,396 thousand in 2024. This level of cash burn is typical for early-stage biotech companies, especially those in clinical development, as they invest heavily in trials and research. For example, comparable early-stage oncology biotechs like OncoSec Medical Inc. (prior to its acquisition) or Mustang Bio, Inc. often reported annual operating cash outflows in the range of $20 million to $50 million, depending on their clinical trial phases. Silexion's burn rate, while increasing, is on the lower end of this spectrum, possibly indicating earlier stage trials or a more focused R&D approach.
• Capital Raises: The company's recent capital raises of over $8 million in January 2025, combined with an ELOC of up to $15 million, are standard mechanisms for biotech companies to secure funding. Many small-cap biotechs, such as Cassava Sciences, Inc. or Veru Inc., frequently utilize public offerings, warrant exercises, and equity lines to fund operations, especially when traditional debt financing is unavailable due to lack of revenue.
• Reverse Stock Splits: The 1-for-9 and 1-for-15 reverse stock splits are common for companies trading on Nasdaq to maintain minimum bid price requirements (typically $1.00). This is a frequent occurrence for development-stage biotechs that experience significant share price depreciation due to ongoing losses and dilution from capital raises. Companies like Sorrento Therapeutics, Inc. or Athersys, Inc. have also resorted to multiple reverse splits to maintain listing compliance.
• Going Concern: The explicit 'going concern' warning is a critical disclosure but not uncommon for pre-revenue biotech companies. It signals high financial risk and dependence on future funding. Many clinical-stage biotechs, including Kura Oncology, Inc. or Arcus Biosciences, Inc. in their earlier stages, have faced similar going concern uncertainties until they achieved significant clinical milestones or secured substantial partnerships.

Management Changes

Corporate Governance

Related Party Transactions

• Research and development expenses included $1,796 thousand from related parties in 2024 (vs. $69 thousand in 2023).
• General and administrative expenses included $2,972 thousand from related parties in 2024 (vs. $48 thousand in 2023).
• Financial expenses included $(1,249) thousand from related parties in 2024 (vs. $83 thousand in 2023).
• As of December 31, 2024, the company had $1 thousand in private warrants to purchase ordinary shares due to related parties (vs. $0 in 2023).
• As of December 31, 2024, the Sponsor Promissory Note (Related Party Promissory Note) had an outstanding balance of $2,961 thousand.
• The PIPE Financing involved Greenstar, LP, an affiliate of the Moringa Sponsor, purchasing 1,482 newly issued Moringa ordinary shares for $2,000 thousand.

Stakeholder Impact

• Shareholders: Significant dilution from multiple reverse share splits and recent capital raises. Potential for further dilution from ELOC and conversion of promissory notes. Risk of substantial loss of investment due to going concern uncertainty.
• Employees: Continued employment is dependent on the company's ability to secure future funding and continue as a going concern. Share-based compensation is a significant component of expenses.
• Creditors: Promissory note holders face risks related to the company's ability to repay or convert notes, though some notes are convertible to equity.
• Customers/Suppliers: Not directly impacted as the company is pre-revenue, but continuity of operations affects future product availability and ongoing relationships.

Next Steps

• Continue evaluating various financing alternatives to fund future research and development activities, general and administrative expenses, and working capital.
• Monitor ongoing activities and make adjustments to ensure business continuity and employee safety amidst geopolitical tensions in Israel.
• EarlyBird Capital, Inc. will sell EBC Shares, and the company will pay any remaining amount due to retire the Underwriters Promissory Note.

Key Dates

Recommendation

The filing reveals a company in a precarious financial position, marked by a significant increase in net losses and cash burn, leading to an explicit "going concern" warning from management. While recent capital raises provide a temporary lifeline, they are dilutive and do not address the fundamental lack of revenue generation. The multiple reverse stock splits indicate severe share price depreciation and a struggle to maintain Nasdaq listing requirements. The high operational costs, particularly in G&A, and the reliance on continuous external financing without a clear path to profitability or significant clinical milestones present a high-risk investment profile. For a seasoned investor, the current financial trajectory and the going concern uncertainty suggest a strong likelihood of further value erosion, making a "sell" recommendation prudent.

Keywords

Silexion Therapeutics, SLXN, Biotechnology, Pancreatic Cancer, siRNA, KRAS mutation, SEC Filing, 8-K, Financial Results, Reverse Stock Split, Going Concern, Capital Raise, Nasdaq, Clinical Stage, Research and Development